Skip to main content

Drug Safety

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Mar 05, 2021

Genentech announced yesterday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for the slowing the rate of decline in pulmonary function in adults SSc-ILD

Read Article

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article

Baricitinib Therapy in Covid-19 Pneumonia

Mar 04, 2021

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery. The key

Read Article

Paucity of Effectiveness Research on Telemedicine in RA

Mar 02, 2021

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address

Read Article

Combo Therapy Boosts Response in Uncontrolled Gout

MedPage Today
Mar 02, 2021

The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.



In a cohort of patients whose gout had been refractory to conventional therapy, co-treatment with

Read Article

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

Mar 01, 2021

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

Read Article

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Feb 26, 2021

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher) https://t.co/9YiGqVr66w

Dr. John Cush @RheumNow( View Tweet )

Feb 25, 2021

Measureable Benefits to Treat-to-Target Management in RA

Feb 24, 2021

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen

Read Article

ANAGO Study - Anakinra for Gout Flare

MedPage Today
Feb 23, 2021

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) was not superior to triamcinolone for relieving gout flares, but had similar effects for pain reduction as the glucocorticoid, a randomized phase II study found.

Read Article

Diagnosis & Treatment of Osteoarthritis Reviewed

Feb 22, 2021

Katz, Arant and Loeser have published a comprehensive open-read overview of osteoarthritis (OA) of the hip and knee in JAMA; underscoring the impact, advances, disappointments and guidelines put forth. 



OA affects an estimated more than 240 million people worldwide, and more

Read Article

Avacopan - Is it Really a Win for ANCA-Associated Vasculitis?

Feb 18, 2021

The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).

Read Article

Checkpoint Inhibitor Use with Pre-existing Autoimmune Disease

Feb 17, 2021

Annals of Internal Medicine reports treating advanced melanoma with immune checkpoint inhibitors (ICI) in patients with pre-existing autoimmune disease (AID) was as effective and safe in those with AID compared to those without AID, although severe colitis occurred more frequently among

Read Article
ACR and Three Societies Agree on HCQ Eye Safety Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity. https://t.co/3ALK3MpOen https://t.co/SzScNXgoqn
Dr. John Cush @RheumNow( View Tweet )
Feb 17, 2021

ACR and Three Societies Agree on HCQ Eye Safety

MedPage Today
Feb 16, 2021

Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity.



The American College of Rheumatology, the American Academy of Ophthalmology, the American Academy of Dermatology, and the Rheumatologic

Read Article
30 #RA pts treated w/ tofacitinib x 12 mos w/ signif improvement in DAS28, CRP, & HAQ and attenuation of further bone loss, as measured by significantly increased osteocalcin, OPG, and vitamin D3, with decreased CTX levels correlating w/ DXA results https://t.co/RSXL38cJvs

Dr. John Cush @RheumNow( View Tweet )

Feb 16, 2021

MIRROR Study: Pegloticase With Methotrexate in Uncontrolled Gout

Feb 15, 2021

Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout.

This exploratory, open-label clinical trial screened 17 patients and treated 14 patients (all men, 49.3 ± 8.7 years) with IV pegloticase with MTX (15

Read Article

RWCS Highlights - Day 3

Feb 15, 2021

Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.

Read Article
EXCEED study in #PsA shows lower responses in women (vs men) treated with either secukinumab or adalimumab. Question is, why? @RWCSmtg @JointMD https://t.co/LFBQi1jtiu
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Congrats to ACR Task Force who published guidelines on RMD drug use w/ COVID vaccines. My views on their recs: 1. I agree, no change most DMARD, biologics 2. I disagree; I would NOT hold Orencia, I would NOT hold JAKi 3. I disagree: I would not hold MTX https://t.co/uSPfvJB8EC https://t.co/SznUJosmpo
Dr. John Cush @RheumNow( View Tweet )
Feb 10, 2021
RheumNow Podcast – Tofacitinib Safety Concerns https://t.co/rqNoiLB3xr https://t.co/rmlw2T0Cif
Dr. John Cush @RheumNow( View Tweet )
Feb 10, 2021
QD Clinic - Sawtooth Steroid Taper How I Taper Steroids - the Sawtooth way https://t.co/PNMV3Pjbxc

Dr. John Cush @RheumNow( View Tweet )

Feb 10, 2021
×